Looks like you’re on the UK site. Choose another location to see content specific to your location
Medtronic study shows benefits of InterStim for overactive bladder
Medtronic has announced new clinical trial data that demonstrates the clinical benefits that its InterStim sacral neuromodulation therapy system offers for people with overactive bladder.
Results from the InSite study have been published in the Journal of Urology, indicating that 82 percent of patients experienced therapeutic success and sustained quality-of-life improvements through this form of treatment at five years.
Specifically, among those with urinary urge incontinence, 45 percent were able to achieve complete continence, with an average reduction of two leaks per day recorded among this group.
In addition, it was shown that patients experienced sustained quality-of-life improvements that were three times greater than what is considered clinically significant.
Linnea Burman, vice-president and general manager of Medtronic's pelvic health and gastric therapies business, said: "These data should give physicians and patients confidence that relief and restored quality of life are possible and we hope this will help encourage the many still suffering from bothersome overactive bladder symptoms to seek help."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard